title: Haemolytic uraemic syndrome associated with gemcitabine.
abstract: Haemolytic uraemic syndrome (HUS) is a rare thromboembolic complication observed in patients with cancer. It is characterised by the clinical triad of acute renal failure, microangiopathic haemolytic anaemia and thrombocytopaenia. It may be associated with a variety of aetiologies, including chemotherapeutic agents such as mitomycin, cisplatin, bleomycin, 5-fluorouracil and, most recently, gemcitabine. We report a 70-year-old patient treated with gemcitabine who developed haemolytic uraemic syndrome.
authors.affiliation: Medical Oncology Service, Hospital de Sabadell, Corporació Sanitària Parc Taulí, Sabadell, Barcelona, Spain.
authors.forename: Irene
authors.initials: I
authors.lastname: Moya-Horno
authors.forename: Rosa
authors.initials: R
authors.lastname: Querol Niñerola
authors.forename: Teresa
authors.initials: T
authors.lastname: Bonfill Abella
authors.forename: Elsa
authors.initials: E
authors.lastname: Dalmau Pórtulas
authors.forename: Enrique
authors.initials: E
authors.lastname: Gallardo-Díaz
authors.forename: Eugeni
authors.initials: E
authors.lastname: Saigí Grau
authors.forename: Carles
authors.initials: C
authors.lastname: Pericay Pijaume
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D002277:Carcinoma / Q000188:drug therapy / Q000473:pathology; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced*; D006801:Humans; D008297:Male; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000473:pathology; D019459:Urothelium / Q000187:drug effects / Q000473:pathology; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D016190:Carboplatin; D000093542:Gemcitabine
references.citation: Nephrol Dial Transplant. 1998 Jan;13(1):76-81
references.pmid: 9481719
references.citation: Arch Intern Med. 1995 Oct 23;155(19):2077-84
references.pmid: 7575067
references.citation: Am J Health Syst Pharm. 1997 Jan 15;54(2):162-70; quiz 197-8
references.pmid: 9117804
references.citation: Kidney Blood Press Res. 1996;19(3-4):205-8
references.pmid: 8887262
references.citation: Cancer. 2004 Jun 15;100(12):2664-70
references.pmid: 15197810
references.citation: Rev Med Interne. 2002 Feb;23(2):189-92
references.pmid: 11876063
references.citation: Am J Hematol. 1990 Jan;33(1):46-9
references.pmid: 2104558
references.citation: Cancer. 1986 Oct 1;58(7):1428-36
references.pmid: 3091244
references.citation: Pathol Oncol Res. 2000;6(4):301-12
references.pmid: 11173665
references.citation: JOP. 2005 Jul 08;6(4):369-74
references.pmid: 16006690
references.citation: Semin Hematol. 1987 Jul;24(3):161-77
references.pmid: 3310241
references.citation: Am J Kidney Dis. 2002 Oct;40(4):E16
references.pmid: 12324937
references.citation: Ren Fail. 1987;10(2):107-13
references.pmid: 3120247